Literature DB >> 15527110

Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.

Wolfgang Wick1, Antje Wick, Wilhelm Küker, Johannes Dichgans, Michael Weller.   

Abstract

Successful management of a heavily pretreated 58-year-old woman with metastatic esthesioneuoblastoma using temozolomide is reported. There is no standard treatment of this tumors with extra- and intracranial manifestations. The response, long term stability and high quality of life using temozolomide for this tumor entity should be recognized.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15527110     DOI： 10.1023/b:neon.0000040826.30636.4a

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  6 in total

1.  Treatment of intracranial metastatic esthesioneuroblastoma.

Authors:  Marc C Chamberlain
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

Review 2.  Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.

Authors:  E A McElroy; J C Buckner; J E Lewis
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

3.  Esthesioneuroblastoma: reflections of a 21-year experience.

Authors:  P A Levine; R Gallagher; R W Cantrell
Journal:  Laryngoscope       Date:  1999-10       Impact factor: 3.325

4.  Treatment of intracranial metastatic esthesioneuroblastoma.

Authors:  Marc C Chamberlain
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

5.  A prospective study on glioblastoma in the elderly.

Authors:  Alba A Brandes; Francesca Vastola; Umberto Basso; Franco Berti; Giampietro Pinna; Antonino Rotilio; Marina Gardiman; Renato Scienza; Silvio Monfardini; Mario Ermani
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

6.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Authors:  W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640
  6 in total
  6 in total

1.  Multimodality Treatment of Pediatric Esthesioneuroblastoma.

Authors:  Rajkumar Venkatramani; Hubert Pan; Wayne L Furman; Jonathan M Marron; Josephine Haduong; Paola Friedrich-Medina; Anita Mahajan; Abhishek Bavle; Hao Wu; Murali Chintagumpala
Journal:  Pediatr Blood Cancer       Date:  2015-10-30       Impact factor: 3.167

2.  Esthesioneuroblastoma methods of intracranial extension: CT and MR imaging findings.

Authors:  Tian Yu; Yi-Kai Xu; Long Li; Fei-Ge Jia; Gang Duan; Yuan-Kui Wu; Hua-Yu Li; Rui-Meng Yang; Jie Feng; Xiang-Hua Ye; Ying-Wei Qiu
Journal:  Neuroradiology       Date:  2009-08-11       Impact factor: 2.804

Review 3.  Esthesioneuroblastoma.

Authors:  Heidi D Klepin; Kevin P McMullen; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2005-11

4.  Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital.

Authors:  David M Mintzer; Sarah Zheng; Michiko Nagamine; Jason Newman; Maria Benito
Journal:  Oncologist       Date:  2010-01-06

5.  Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.

Authors:  M Preusser; M Hutterer; M Sohm; O Koperek; K Elandt; K Dieckmann; D Prayer; C Marosi
Journal:  J Neurooncol       Date:  2009-10-10       Impact factor: 4.130

Review 6.  Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment.

Authors:  Piotr Czapiewski; Michał Kunc; Johannes Haybaeck
Journal:  Oncotarget       Date:  2016-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.